<DOC>
	<DOCNO>NCT00834028</DOCNO>
	<brief_summary>This project include least 40 patient hepatocellular carcinoma ( HCC ) receive transcatheter arterial chemoembolization ( TACE ) sole method management . The serum collect 3rd 7th day TACE . The serum level vascular endothelial growth factor , angiopoietin 2 , endostatin cathepsin L determine . All patient evaluate accord TNM system cancer stag 3 month session treatment . The vascularity tumor , drug dose use embolization , area infarction record . These data compare clinical course patient obtain suitable way management patient .</brief_summary>
	<brief_title>Recurrence Distant Metastases Hepatocellular Carcinoma Treated Transcatheter Arterial Chemoembolization</brief_title>
	<detailed_description>Transcatheter arterial chemoembolization ( TACE ) traditional method palliative management patient hepatocellular carcinoma ( HCC ) . This method cause tissue hypoxia area embolization . Several proangiogenic factor induce condition hypoxia . This may possibility promote proliferation residual cancer cell . However , study clarify issue . This project determine serial change serum proangiogenic factor ( vascular endothelial growth factor , angiopoietin 2 ) , antiangiogenic factor ( endostatin ) cathepsin L TACE . These data compare clinical course patient obtain suitable way management patient . This project include least 40 patient HCC receive TACE sole method management . The serum collect 3rd 7th day TACE . The serum level vascular endothelial growth factor , angiopoietin 2 , endostatin cathepsin L determine . All patient evaluate accord TNM system cancer stag 3 month session treatment . The vascularity tumor , drug dose use embolization , area infarction record .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>patient hepatocellular carcinoma treat transcatheter arterial chemoembolization patient hepatocellular carcinoma unable treat transcatheter arterial chemoembolization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>vascular endothelial growth factor</keyword>
	<keyword>angiopoietin</keyword>
	<keyword>cathepsin</keyword>
</DOC>